Join the Oncology Voice Network. Join for Free
The ULTIMATE Checklist for New MSLs
MSL Medical Science Liaison Samantha Buckley KOL meetings MSL certification

The ULTIMATE Checklist for New MSLs


Share This Article


Summary

In this episode, Samantha Buckley discusses her journey from clinical pharmacy to becoming an MSL, highlighting the value of personalized cover letters and MSL certification. She delves into territory mapping, strategic planning, and the art of relationship-building as key components of the MSL role. Samantha emphasizes the importance of effective KOL meetings and the insights they provide. She also touches on cross-functional collaboration within Medical Affairs and shares the rewarding aspects of being an MSL. The episode concludes with encouragement for aspiring MSLs and closing remarks.

My guest this week is Samantha Buckley, PharmD. Medical Science Liaison at SOBI who discusses the ultimate checklist for new MSLs.

Learn more about…

👉 The ONE differentiating factor to her MSL job search success
👉 What is day one like for an MSL
👉 Training and certification
👉 The ART of MSLing
👉 Prep for initial KOL meetings

Click for Source
MSL, Medical Science Liaison, Samantha Buckley, KOL meetings, MSL certification

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Struggle With KOL Access in Todays World
Partner Avatar MSL Talk: Tom Caravela, Carsten Schnatwinkel, Jeanna Cooper

The Struggle With KOL Access in Todays World

Podcast
Surround to Succeed: Building a Motivational Network
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

Surround to Succeed: Building a Motivational Network

Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Explore OVN